跳至主要内容
临床试验/NCT00097812
NCT00097812已完成3 期

A Study to Assess the Safety, Tolerability, and Efficacy of Switching Patients Currently on Oral Bisphosphonate to Zoledronic Acid

Novartis Pharmaceuticals25 个研究点 分布在 2 个国家目标入组 220 人开始时间: 2004年5月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
220
试验地点
25
主要终点
To compare % change in Lumbar Spine BMD from Baseline to Month 12 in ZOL (annual i.v. infusion) vs Alendronate (weekly oral) osteoporotic post-menopausal women populations

研究概览

简要总结

The purpose of this study is to assess bone mineral density in patients switching from an oral bisphosphonate to zoledronic acid, compared to those staying on the oral bisphosphonate.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
45 Years 至 79 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Post-menopausal women between 45 and 79 years of age
  • Must be osteopenic/osteoporotic
  • Treatment with oral bisphosphonate for at least 1 year

排除标准

  • Any woman of child bearing potential
  • Treatment with other bone active agents
  • Other protocol-defined inclusion/exclusion criteria may apply.

结局指标

主要结局

To compare % change in Lumbar Spine BMD from Baseline to Month 12 in ZOL (annual i.v. infusion) vs Alendronate (weekly oral) osteoporotic post-menopausal women populations

次要结局

  • To compare Biomarkers of bone turnover in the annual Zol i.v. and weekly alendronate populations
  • To demonstrate continued bone remodeling by evaluation of bone biopsies in a subset of patients
  • To assess patient preferences for annual i.v. therapy compared to weekly oral therapy through a patient questionnaire

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (25)

Loading locations...

相似试验